Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03484819
Title Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Cancer Center Birmingham Alabama 35233 United States Details
University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa 52242 United States Details
HaysMed Hays Kansas 67601 United States Details
University of Kansas Cancer Center Kansas City Kansas 66160 United States Details
Olathe Health Cancer Center Olathe Kansas 66061 United States Details
Ascension Via Christi - Pittsburg Pittsburg Kansas 66762 United States Details
Salina Regional Health Center Salina Kansas 67401 United States Details
University of Kansas Health System Saint Francis Campus Topeka Kansas 66606 United States Details
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205 United States Details
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 United States Details
Mayo Clinic in Rochester Rochester Minnesota 55905 United States Details
University Health Truman Medical Center Kansas City Missouri 64108 United States Details
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon New Hampshire 03756 United States Details
Wake Forest University Health Sciences Winston-Salem North Carolina 27157 United States Details
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field